Related Experiment Video
Updated: Jun 24, 2025
12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
12.7K
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies
Malgorzata Bobrowicz1, Aleksandra Kusowska1,2,3, Marta Krawczyk1,3,4
1Department of Immunology, Medical University of Warsaw, Warsaw, Poland.
Oncoimmunology
|June 7, 2024
Summary
Rituximab-resistant lymphoma cells show reduced CD37 levels, impacting anti-CD37 antibody efficacy. However, CD37-targeted CAR T-cell therapy remains effective, offering a promising alternative for aggressive lymphomas.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- First-line therapy for lymphoma, rituximab plus chemotherapy (R-CHOP), results in relapse for about 40% of patients.
- Novel therapeutic strategies are crucial for treating aggressive lymphomas.
- Rituximab-resistant (RR) cell lines serve as models to investigate resistance mechanisms to R-CHOP.
Purpose of the Study:
- To investigate the role of CD37 in rituximab resistance.
- To explore the interaction between CD20 and CD37.
- To evaluate the efficacy of anti-CD37 immunotherapies in rituximab-resistant and CD20 knockout models.
Main Methods:
- Establishment and characterization of rituximab-resistant (RR) and CD20 knockout (KO) lymphoma cell lines.
- Analysis of CD37 expression levels and its interaction with CD20.
- Assessment of anti-CD37 monoclonal antibody (mAb) efficacy, including complement-dependent cytotoxicity (CDC) and internalization rates.
- Evaluation of CD37-directed chimeric antigen receptor (CAR) T-cell activity.
Main Results:
- RR cells exhibit significant downregulation of CD37.
- CD20 and CD37 form a complex, with CD20 potentially stabilizing CD37 on the cell membrane.
- Anti-CD37 mAb-mediated CDC is diminished in RR and CD20 KO cells, partially restored by lysosome inhibition.
- Anti-CD37 mAb internalization is increased in CD20 KO cells, suggesting potential for antibody-drug conjugates (ADCs).
- CD37-directed CAR T-cell efficacy is unaffected by CD37 downregulation.
Conclusions:
- A novel mechanism of CD37 regulation involving CD20 interaction is identified.
- CD37 downregulation impacts anti-CD37 mAb efficacy but not CAR T-cell therapy.
- Findings provide insights for optimizing anti-CD37 immunotherapies in lymphoma treatment.
Related Concept Videos
01:27Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
01:22T Cell Activation and Clonal Selection
706
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
706
01:27Cytotoxic T Cells-mediated Immune Response
891
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
891